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Age-specific and sex-specific weight gain norms to
monitor antiretroviral therapy in children in
low-income and middle-income countries
Marcel Yotebienga,b, Tammy Meyersc, Frieda Behetsd,
Mary-Ann Daviese, Olivia Keiserf, Kapella Zacharia Ngonyanig,
Rita E. Lyamuyah, Azar Kariminiai, Rawiwan Hansudewechakulj,
Valeriane Leroyk,l, Sikiratou Koumakpaim, Jamie Newmann and
Annelies Van Rieb
Background: Viral load and CD4% are often not available in resource-limited settings
for monitoring children’s responses to antiretroviral therapy (ART). We aimed to
construct normative curves for weight gain at 6, 12, 18, and 24 months following
initiation of ART in children, and to assess the association between poor weight gain and
subsequent responses to ART.
Design: Analysis of data from HIV-infected children younger than 10 years old from
African and Asian clinics participating in the International epidemiologic Databases to
Evaluate AIDS.
Methods: The generalized additive model for location, scale, and shape was used to
construct normative percentile curves for weight gain at 6, 12, 18, and 24 months
following ART initiation. Cox proportional models were used to assess the association
between lower percentiles (<50th) of weight gain distribution at the different time
points and subsequent death, virological suppression, and virological failure.
Results: Among 7173 children from five regions of the world, 45%were underweight at
baseline. Weight gain below the 50th percentile at 6, 12, 18, and 24 months of ART was
associated with increased risk of death, independent of baseline characteristics. Poor
weight gain was not associated with increased hazards of virological suppression or
virological failure.
Conclusion: Monitoring weight gain on ART using age-specific and sex-specific
normative curves specifically developed for HIV-infected children on ART is a simple,
rapid, sustainable tool that can aid in the identification of children who are at increased
risk of death in the first year of ART.
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Introduction
More than three million children live with HIV
worldwide, of whom more than 90% live in sub-Saharan
Africa [1]. In the absence of antiretroviral therapy (ART),
a third of children infected perinatally will not survive to
their first birthday, and more than half will not survive to
their second birthday [2]. Successful initiation of ART in
children is followed by a rapid decline in viral load, a
rebound in CD4þ cell count, a reduction in mortality,
and a rapid gain in weight, especially in the first
6–12 months of ART [3–7].
In developed nations, routine laboratory tests (HIV viral
load, CD4þ cell count) are performed every 3–4 months
to monitor patients with HIV receiving ART [8]. The
measurement of viral load and to some extent that of
CD4þ cell count requires expensive and sophisticated
technologies that cannot always be easily transferred or
sustained in resource-poor settings. Recent studies in
adults showed that routine CD4þ monitoring had small
but significant benefits over clinical monitoring, [9,10]
and viral load monitoring had no significant additional
benefit over CD4þ monitoring [9]. Similar benefits of
routine monitoring of CD4þ cell count were reported in
the only such trial conducted in children so far [11]. In
addition, this trial demonstrated that monitoring of
weight gain on ART is a sensitive indicator of first-line
treatment failure in African children [11], supporting the
WHO recommendations that in settings in which viral
load is unavailable, clinical parameters, particularly the
improvement in growth, be used for monitoring ART,
supported where possible with CD4þ cell count
monitoring [12].
Contrary to viral load, which has a clear and simple target
cut-point (below detection limit), cut-points for weight
gain that correlate with subsequent treatment outcomes
have not been clearly established. One important
difficulty in establishing those references for children
resides in the fact that changes in weight strongly depend
on age and sex. Two age-stratified and sex-stratified
normative percentiles curves are almost ubiquitously used
in pediatric care: the WHO ‘Road to Health’ for attained
weight-for-age [13], and the Fels Institute growth charts
for growth velocity [14,15]. In a previous analysis [16]
using data from a single clinic in Soweto, South Africa, we
demonstrated that the WHO and the Fels Institute
growth charts were not valid for use in children receiving
ART. Furthermore, although the effectiveness of ART is
the same in high-income, middle-income, and low-
income countries [17,18], the prevalence of malnutrition
and opportunistic infections at ART initiation varies by
region, which could affect weight gain following ART
initiation.
In this study, we aimed to construct international
reference standards for gains in weight at 6, 12, 18,
and 24 months following ART initiation and identify the
centile curves of weight gain that are correlated with
subsequent treatment failure and death.
Methods
Data and data sources
Data for this analysis were provided by the International
Epidemiologic Databases to Evaluate AIDS, a US
National Institutes of Health initiative launched in
2005 to establish an international research consortium
to address research questions not answerable by single
cohorts. The initiative funds seven regional data centers of
which five contributed data for this analysis: the Asia-
Pacific region which includes the Therapeutics Research,
Education, and AIDS Training in Asia (TREAT Asia)
HIV Observational Database and includes data from
Cambodia, India, Indonesia, Malaysia, Thailand, and
Vietnam; the West African Database on Antiretroviral
Therapy Collaboration which includes cohorts from
Benin, Burkina Faso, Coˆte d’Ivoire, Ghana, Mali, and
Senegal; the Central African region with participating
sites from Burundi, Cameroon, Democratic Republic of
Congo, and Rwanda; the Eastern Africa regional data
centers which combine data from cohorts in Kenya,
Tanzania, and Uganda; and the Southern African region
with data from Lesotho, Malawi, Mozambique, South
Africa, Zambia, and Zimbabwe. Detailed descriptions of
the database and the main clinical outcomes have been
reported elsewhere [19,20].
Statistical analysis
Assessing the homogeneity of weight gain over time by
region
To assess the homogeneity of gains in weight, we
computed the median weight gain from ART initiation
for each 3-month interval through 24months of ARTand
plotted the values for each of the five regions. The plotted
curves were visually inspected and data were merged if the
gains overtime appeared homogeneous across regions
(parallel plots). A quantile regression model with weight
as response variable and time, region, and the interaction
terms between region and time as dependent variable was
also used to formally assess whether the change in weight
over time after ART initiation varies by region.
Construction of reference curves for weight gain at 6,
12, 18, and 24 months after antiretroviral therapy
initiation
We calculated weight gain at each of the 6, 12, 18, and 24
months time points for each individual child. Response
curves were obtained by smoothing measurements over
the chronological age at time of measurement using
locally weighted quadratic regression [21]. Estimates of
weight gain were then obtained by subtracting the
response curve estimates at each time point from the
baseline (at ART initiation) estimates (see reference [16]
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for a detailed description of the method). For visits that
fell within 3 months of the cut-point, the weight gain
was adjusted simply by dividing the measured weight
gain by the exact time interval since ART initiation
and multiplying it by the corresponding time interval.
For example, in a child whose closest weight to 6 months
was measured at 5 months, the estimate of weight gain
at 6 months was obtained by dividing the difference
between the smoothed value of weight at 5 months and
the value at ART initiation by 5, and then multi-plying it
by 6.
To obtain the normative reference percentile curves, we
used methods similar to those used by the WHO to
construct recent international growth curves [13]. The 6,
12, 18, and 24 months estimates of weight gain were
regressed on chronological age using the generalized
additive model for location, scale, and shape, a method
that requires a parametric distribution assumption for
the response variable while allowing the modeling of
the distribution parameter as nonparametric (smooth)
functions of the explanatory variables [22]. For the
response variable, we assumed a Box-Cox power
exponential distribution with four parameters relating
to location (m, median), scale (s, coefficient of variation),
skewness (y, transformation for symmetry), and kurtosis
(t, power exponential parameter), respectively [23].
To specify the model, the user must choose the number
of degrees of freedom (df) to be used for each parameter.
Starting with the simplest model that includes age and
the fitting of m and s curves while keeping the degree
of freedom for y and t fixed at zero, we searched
for df(m) and then df(s) that minimized the global
deviance as indicated by the generalized Akaike
Information Criterion (with penalty 3 for each degree
of freedom used). In the next step, using the df(m) and
df(s) selected in the previous, we sequentially searched
for the df(y) and df(t) that minimized the global deviance.
In the last step, Q statistic [24] and worm plots [25]
were used to fine tune the selected df(m), df(s), df(y), and
df(t) [23]. Because of the high variability of weight gain
in children after the age of 10 years, only data from
children younger than 10 years were used to facilitate
model convergence.
Association of lower weight gain with subsequent
response to antiretroviral therapy
Three outcomes were considered: time to death
(survival), time to viral suppression (first viral load less
than 400 copies/ml after ART initiation), and time to
virologic failure. The outcome of virologic failure
occurred when a child met one of three conditions: a
viral load measurement more than 1000 copies/ml after at
least 1 year of ART, two consecutive viral load
measurements more than 400 copies/ml after initial
virologic suppression, or failure to ever achieve virolo-
gical suppression after at least 1 year of ART.
For each of the three outcomes, separate Cox pro-
portional hazard models were fitted for the 3rd, 10th,
25th, 33rd, and 50th centiles as predictors for each of the
6, 12, 18, and 24 months time points. Age at ART
initiation (<2 years, 2–4 years, 5–9 years), weight-for-
age z score (WAZ) (<"3SD,"3SD# to<"2SD,"2SD
# to <"1SD, and $"1SD) [26], baseline CD4% (<15,
15–25, >25%), an interaction term between WAZ and
the centiles (in case the association differed by baseline
WAZ), and year of ART initiation were included in
the initial model for death. Baseline viral load ($5 log,
<5 log copies/ml) was also included in the initial models
for the two virological outcomes. Using a stepwise
backward selection procedure and the Wald test, all
covariates that did not contribute significantly to the fit of
each multivariate model were dropped. The hazard ratio
and 95% confidence interval (CI) from each of the final
models are reported. All variables included in the model
met the proportional hazards assumption formally
evaluated using the Kolmogorov-type supremum test [27].
Analyses were done using SAS 9.2 (SAS Institute, Cary,
North Carolina, USA). All tests were conducted using a
two-sided 0.05 significance level, without correction for
multiple comparisons (or uncertainty because of model
selection). The study was approved by the Office of
Human Research Ethics at the University of North
Carolina at Chapel Hill.
Results
Description of cohorts
Of the 11 802 HIV-infected children younger than
10 years of age in the combined dataset, 8628, 6825,
5241, and 3883, were on ART for at least 6, 12, 18, and
24 months, respectively. Of those children, 7173, 5029,
4288, and 3072 had sufficient data to be included in the
analysis at each time point. Half (3657 or 51%) were from
Southern Africa, 23% from Eastern Africa,13% fromAsia,
9% from Western Africa, and 4% from Central Africa
(Table 1). The change in weight overtime following ART
initiation was homogeneous across regions. All P values
for the four interaction terms between region and time
were more than 0.20 (Figure 3 and Table 3 supplemental
material, http://links.lww.com/QAD/A596).
Few (3.5%) children initiated ART before 2004, the
majority (78%) initiated between 2005 and 2007, and the
remainder (7%) initiated in 2008 and 2009 (Table 1). Half
(52%) were male. At the time of ART initiation, 23%
were aged 1 year or younger, and 45% were underweight
for age (WAZ #"2 SD). Of the 5171 (72.1%) children
with pre-ART CD4% available, 74% were severely
immunosuppressed (CD4% <15%). Of the 2615 (36.5%)
children with pre-ART viral load, 64% had values at least
5 log copies/ml. Children from the Eastern and Southern
Africa regions were less likely to be underweight-for-age
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at ART initiation compared with those from other
regions (P< 0.01).
The median duration of follow-up was 23.9 months
following ART initiation. A total of 111 deaths were
recorded, of which 68 (61.3%) occurred between 6 and
12 months, 20 (18.0%) between 12 and 18 months, 12
(10.8%) between 18 and 24 months, and 11 (10.0% after
24 months of ART (Table 5 supplemental material,
http://links.lww.com/QAD/A596).
Growth curves and distribution of 6, 12, 18, and
24 months weight gain
Figures 1 and 2 present the age-specific and sex-specific
distributions of cumulative weight gained at 6, 12, 18, and
24 months after ART initiation. For example, for a boy
who started ARTat the age of 6 months, at the 6, 12, 18,
and 24 months visits, to remain consistently above the
33rd percentile curves for weight gain, he must have
cumulatively gained at least 2.04, 3.42, 4.52, and 5.50 kg,
at the corresponding visit, irrespective of his initial weight
(Tables 6a–9b, supplemental material, http://links.lww.
com/QAD/A596).
Association of poor postantiretroviral therapy
weight gain (<50th percentile) and subsequent
survival, viral suppression and virologic failure
Children with poor weight gain at 6 and 12 months of
ART had a statistically higher hazard of death than those
with good weight gain (Table 2). After adjustment for
WAZ at ART initiation, the hazard ratios comparing
children below the 33rd percentile of weight gain with
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Fig. 1. Six-month and 12-month sex-specific and age-specific weight gain reference curves in children. (a) Centile curves for
6 months post-ART weight gain in females. (b) Centile curves for 6 months post-ART weight gain in males. (c) Centile curves for
12months post-ARTweight gain in females. (d) Centile curves for 12months post-ARTweight gain in males. Curves were obtained
using Box Cox power exponential (BCPE) distribution and the generalized additive model for location, scale, and shape. Model for
female at 6 months (a): BCPE (age, df(m)¼ 12.9, df(s)¼0.2, df(y) ¼1, df(t)¼3). Model for males at 6 months (b): BCPE (age,
df(m)¼9.9, df(s)¼0.2, df(y)¼2, df(t)¼2). Model for females at 12 months (c): BCPE (age, df(m)¼4.8, df(s)¼0, df(y)¼1, df(t)¼0).
Model for males at 12 months (d): BCPE (age, df(m)¼ 4.8, df(s)¼0, df(y) ¼1.3, df(t)¼0). df, degrees of freedom.
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those above was 2.97 (95% CI: 2.03, 4.36) at 6 months
and 2.28 (95% CI: 1.23, 4.22) at 12 months. A dose–
response effect was observed for these associations with
higher hazard ratios at lower weight gains, especially for
the first 12 months of ART. For example, children
with weight gains at the lowest (3rd) percentile had a
nine-fold greater hazard of subsequent death compared
with children with greater weight gain. The increased risk
of death with lower weight gains persisted after 18 and
24 months of ART, but the estimates were imprecise due
to the limited number of deaths that occurred after
18 months.
No statistical association was observed between the
distribution of weight gain and time to virological
suppression or time to virologic failure (Table 2).
Discussion
Data from recent randomized clinical trials in children
[11] and in adults [10] show that routine laboratory
monitoring for antiretroviral drug toxicity may not
be needed in children and that CD4þ monitoring
provides a small but significant reduction in disease
progression or death after the second year on ART.
In adults, despite results from a large multicountry
cohort study showing that virological monitoring
might have some added benefit [28], particularly after
2 years, results from a clinical trial shows that adding
viral load to CD4þ monitoring provided no further
benefits [10]. The trial in children identified monitoring
weight gain as a sensitive indicator of first-line treatment
failure [11].
106 AIDS 2015, Vol 29 No 1
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Fig. 2. Eighteen-month and 24-month sex-specific and age-specific weight gain reference curves in children. (a) Centile curves
for 18 months post-ART weight gain in females. (b) Centile curves for 18 months post-ART weight gain in males. (c) Centile curves
for 24 months post-ART weight gain in females. (d) Centile curves for 24 months post-ART weight gain in males. Curves were
obtained using Box Cox power exponential (BCPE) distribution and the generalized additive model for location, scale, and shape.
Model for females at 18 months (a): BCPE (age, df(m) ¼4.1, df(s)¼0, df(y) ¼3, df(t)¼0). Model for males at 18 months (b): BCPE
(age, df(m)¼6.1, df(s)¼0, df(y) ¼2, df(t)¼0). Model for females at 24 months (c): BCPE (age, df(m)¼3, df(s)¼1.5, df(y) ¼0.8,
df(t)¼0). Model for males at 24 months (d): BCPE (age, df(m)¼3.8, df(s)¼1.22, df(y) ¼1, df(t)¼0). df, degrees of freedom.
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Growth monitoring is routinely performed in the follow-
up of children [26]. However, neither of the commonly
used WHO and Fels normative references growth curves
are valid for HIV-infected children starting ART [16].
This is mainly because the origin used for both of these
curves is birth, although ART initiation in resource-
limited settings generally does not happen at birth. In this
study, we were able to construct normative reference
standards for weight gain at 6, 12, 18, and 24 months of
ART for HIV-infected children younger than 10 years. At
6 and 12 months on ART, the hazard of dying in children
whose weight gain was below the 33rd percentile was at
least twice that of children who gained more weight. The
strength of the association increased with decreasing
weight gain.
We did not observe a correlation between weight gain
and virological suppression or virological failure. This is
contrary to findings from our single-clinic cohort study of
South African children [16]. We speculate that it is
because of selection bias, as viral load monitoring was not
routinely available or accessible in most clinics and
regions. In most regions outside of South Africa, children
in routine care are only assessed by viral load in the
presence of a clinical indication. As such, children with
available viral load measurements are not representative of
all children on ART.
The large sample size and extended follow-up allowed us
to construct reference distributions through 24 months,
and inclusion of five regions representing the regions of
the world where virtually all pediatric HIV cases are
found were important strengths of our study. Unfortu-
nately, we did not have adequate and unbiased data on
viral load and CD4þ to assess the potential of monitoring
weight gain alone or in combination with CD4þ as
predictors of poor response to ART.Moreover, we had to
limit the analysis to children 10 years or younger because
of the high heterogeneity of weight gain after 10 years of
age. [26] Finally, because of the open nature of the
cohorts, occurrence of deaths and loss to follow up,
numbers of children included in the analysis reduced with
longer follow-up time points. The data thus need to be
interpreted conditional on surviving and remaining on
ART and in care to the time point of interest.
In conclusion, in areas with limited access to viral load or
CD4þ measurement, monitoring weight gain post-ART
using normative data developed specifically for HIV-
infected children on ART could be a simple and highly
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Table 2. Association between lower percentile of weight gains at 6, 12, 18, and 24 months of antiretroviral therapy and time to mortality,
virological suppression, and virological failure.
Time to death after 6 months Time to virological suppressiona Time to virological failureb
Hazard ratio (95% CI) Hazard ratio (95% CI) Hazard ratio (95% CI)
Crude Adjustedc Crude Adjustedd Crude Adjustede
Percentile Weight gain at 6 months after ART initiation
3rd 7.61 (4.64, 12.48) 9.20 (5.51, 15.34) 0.95 (0.69, 1.30) 1.18 (0.86, 1.62) 1.85 (1 02, 3.36) 1.10 (0.46, 2.68)
10th 6.86 (4.62, 10.20) 8.61 (5.74, 12.92) 1.01 (0.83, 1.21) 1.11 (0.92, 1.34) 1.50 (1.02, 2.21) 0.76 (0.43, 1.34)
25th 3.18 (2.19, 4.62) 4.17 (2.84, 6.12) 0.92 (0.83, 1.02) 0.93 (0.84, 1.03) 1.12 (0.91, 1.37) 1.10 (0.85, 1.41)
33rd 2.30 (1.59, 3.34) 2.97 (2.03, 4.36) 0.95 (0.87, 1.04) 0.95 (0.87, 1.04) 1.01 (0.84, 1.21) 0.90 (0.72, 1.13)
50th 1.45 (0.99, 2.12) 1.80 (1.22, 2.66) 0.93 (0.86, 1.01) 0.91 (0.84, 0.99) 0.98 (0.83, 1.15) 0.95 (0.78, 1.16)
Weight gain at 12 months after ART initiation
3rd 5.96 (2.65, 13.40) 7.33 (3.20, 16.78) 1.07 (0.81, 1.40) 1.11 (0.86, 1.46) 1.21 (0.67, 2.21) 0.92 (0.45, 1.91)
10th 3.25 (1.60, 6.60) 4.05 (1.96, 8.37) 0.96 (0.81, 1.15) 0.99 (0.83, 1.18) 1.15 (0.80, 1.66) 0.82 (0.49, 1.37)
25th 1.82 (0.98, 3.38) 2.21 (1.17, 4.17) 1.00 (0.90, 1.12) 1.01 (0.90, 1.12) 0.98 (0.79, 1.21) 0.94 (0.72, 1.23)
33rd 1.88 (1.03, 3.41) 2.28 (1.23, 4.22) 1.00 (0.90, 1.10) 0.99 (0.89, 1.09) 0.99 (0.81, 1.20) 0.91 (0.72, 1.15)
50th 1.39 (0.76, 2.54) 1.64 (0.88, 3.04) 0.97 (0.88, 1.07) 0.95 (0.86, 1.04) 0.92 (0.77, 1.10) 0.90 (0.72, 1.11)
Weight gain at 18 months after ART initiation
3rd – – 0.94 (0.70, 1.25) 1.11 (0.74, 1.67) 1.00 (0.52, 1.93) 0.61 (0.22, 1.68)
10th 1.55 (0.46, 5.20) 1.88 (0.55, 6.43) 1.06 (0.89, 1.26) 0.88 (0.69, 1.12) 0.93 (0.64, 1.34) 0.83 (0.50, 1.36)
25th 1.98 (0.86, 4.58) 2.41 (1.02, 5.68) 1.01 (0.90, 1.13) 0.90 (0.77, 1.05) 0.93 (0.74, 1.17) 0.91 (0.66, 1.24)
33rd 1.59 (0.70, 3.63) 1.92 (0.82, 4.48) 0.98 (0.89, 1.09) 0.98 (0.85, 1.12) 0.92 (0.75, 1.13) 0.84 (0.65, 1.10)
50th 1.90 (0.81, 4.49) 2.32 (0.97, 5.58) 0.94 (0.85, 1.03) 0.93 (0.81, 1.06) 0.99 (0.81, 1.19) 0.96 (0.76, 1.21)
Weight gain at 24 months after ART initiation
3rd 2.76 (0.35, 21.53) 3.34 (0.42, 26.34) 0.75 (0.54, 1.02) 0.79 (0.52, 1.21) 1.31 (0.78, 2.21) 1.21 (0.56, 2.64)
10th 2.21 (0.48, 10.23) 2.87 (0.61, 13.48) 0.97 (0.80, 1.18) 0.83 (0.64, 1.08) 1.17 (0.81, 1.68) 1.31 (0.79, 2.16)
25th 3.90 (1.19, 12.80) 4.80 (1.44, 15.93) 1.00 (0.88, 1.14) 0.89 (0.75, 1.06) 1.05 (0.81, 1.35) 0.98 (0.69, 1.40)
33rd 5.65 (1.50, 21.28) 7.17 (1.87, 27.44) 0.93 (0.82, 1.04) 0.87 (0.74, 1.02) 0.95 (0.75, 1.20) 0.87 (0.64, 1.18)
50th 4.79 (1.03, 22.15) 5.99 (1.28, 28.08) 0.93 (0.83, 1.04) 0.92 (0.79, 1.02) 0.90 (0.73, 1.11) 0.89 (0.68, 1.18)
ART, antiretroviral therapy.
aViral load # 400 HIV RNAcopies/ml.
bViral load measurement after at least 1 year of ART above 1000copies/ml, two consecutive viral load measurements >400 copies/ml after initial
virologic suppression, or failure to achieve virological suppression after at least 1 year of ART.
cAdjusted for baseline weight-for-age z scores (WAZ).
dAdjusted for baseline age, viral load, and region.
eAdjusted for baseline age, viral load, and region.
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valuable tool to identify those children at highest risk
of death.
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